- Home
- ANVS vs GNLX Comparison
ANVS vs GNLX Comparison
Compare ANVS & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- GNLX
- Stock Information
- Founded
- ANVS 2008
- GNLX 2001
- Country
- ANVS United States
- GNLX United States
- Employees
- ANVS N/A
- GNLX N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- ANVS Health Care
- GNLX Health Care
- Exchange
- ANVS Nasdaq
- GNLX Nasdaq
- Market Cap
- ANVS 54.6M
- GNLX 96.6M
- IPO Year
- ANVS 2020
- GNLX 2023
- Fundamental
- Price
- ANVS $2.18
- GNLX $2.87
- Analyst Decision
- ANVS Strong Buy
- GNLX Strong Buy
- Analyst Count
- ANVS 5
- GNLX 4
- Target Price
- ANVS $30.25
- GNLX $17.75
- AVG Volume (30 Days)
- ANVS 616.9K
- GNLX 151.1K
- Earning Date
- ANVS 08-14-2025
- GNLX 08-13-2025
- Dividend Yield
- ANVS N/A
- GNLX N/A
- EPS Growth
- ANVS N/A
- GNLX N/A
- EPS
- ANVS N/A
- GNLX N/A
- Revenue
- ANVS N/A
- GNLX N/A
- Revenue This Year
- ANVS N/A
- GNLX N/A
- Revenue Next Year
- ANVS N/A
- GNLX N/A
- P/E Ratio
- ANVS N/A
- GNLX N/A
- Revenue Growth
- ANVS N/A
- GNLX N/A
- 52 Week Low
- ANVS $1.11
- GNLX $1.60
- 52 Week High
- ANVS $17.88
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- ANVS 43.14
- GNLX 52.48
- Support Level
- ANVS $2.52
- GNLX $2.75
- Resistance Level
- ANVS $3.18
- GNLX $3.17
- Average True Range (ATR)
- ANVS 0.31
- GNLX 0.25
- MACD
- ANVS -0.10
- GNLX 0.01
- Stochastic Oscillator
- ANVS 5.38
- GNLX 44.74
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.